LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...

BioArctic AB's (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ?

The Peripheral and Central Nervous System Drugs advisory committee agreed with the FDA’s own assessment that the results of the CLARITY-AD study confirmed that Leqembi (lecanemab) conferred a ...